Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine for REM sleep behavior disorder
ChiCTR2100048875Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of agomelatine in REM sleep behavior disorder (RBD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Alleviation rate of REM sleep without atonia detected by polysomnography. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
agomelatine
03
Conditions
REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on ChiCTR2100048875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048875.